Cartesian Therapeutics, Inc. — Director's Dealing 2024

Aug 14, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-08-12

Reporting Person: BARABE TIMOTHY C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-12	Common Stock	P	7500	$12.70	Acquired	21766	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$19.656	2034-01-01	Common Stock (7600)	7600	Direct

Footnotes

F1: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F2: This award will vest in 36 equal monthly installments, so that it shall be fully vested on the third anniversary of the date of grant.